Mixed results for PTC Duchenne drug put spotlight on EU approval
Bio Pharma Dive
JUNE 21, 2022
A confirmatory study of PTC Therapeutics’ muscular dystrophy treatment Translarna missed its main goal, although the company highlighted the trial’s overall positive results.
Let's personalize your content